CJC-1295 with DAC (CJC-1295 DAC)
Long-Acting Growth Hormone Releasing Hormone Analog | Extended Release
Community Research
Join others researching CJC-1295 with DAC — share findings, ask questions, and learn from real experiences
Modified growth hormone releasing hormone engineered for extended duration via albumin-binding technology. DAC binds to albumin, extending half-life and providing continuous GHRH receptor stimulation.
DAC binds to albumin, extending half-life to 6-8 days and providing continuous GHRH receptor stimulation for sustained GH/IGF-1 elevation.
Molecular Data
Tyrosine
Position 1
Alanine
Position 2
Aspartic Acid
Position 3
Position 4
Isoleucine
Position 5
Phenylalanine
Position 6
Threonine
Position 7
Asparagine
Position 8
Serine
Position 9
Position 10
Arginine
Position 11
Lysine
Position 12
Valine
Position 13
Leucine
Position 14
Position 15
Glutamine
Position 16
Position 17
Position 18
Position 19
Position 20
Position 21
Position 22
Position 23
Position 24
Position 25
Position 26
Position 27
Position 28
Position 29
Position 30
Research Indications
Continuous growth hormone release for 6-8 days per injection.
Significantly elevates IGF-1 levels for extended periods.
Weekly dosing ideal for simple administration.
Continuous GH elevation promotes lipolysis and fat metabolism.
Sustained anabolic environment supports muscle protein synthesis.
Accelerated healing and recovery from exercise or injury.
Dosing Protocols
Subcutaneous injection is the preferred route for DAC variant.
Conservative Anti-Aging
1mg
Once weekly
SubQ
Standard Protocol
2mg
Split Dosing
Twice weekly (Mon/Thu)
Loading Protocol
2mg first week, then 1mg
Weekly
Reconstitution Instructions
CJC-1295 with DAC peptide vial
Bacteriostatic water (2-5mL)
Insulin or 1mL syringes
Alcohol prep pads
1 Clean both vial tops with alcohol and dry completely
2 2mg vial: Add 1mL bacteriostatic water (creates 2mg/mL)
3 5mg vial: Add 2.5mL bacteriostatic water (creates 2mg/mL)
4 Inject water slowly to prevent foaming
5 Let sit 5 minutes before gently rolling to mix
6 Solution may appear slightly cloudy initially
7 Label with date and concentration immediately
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
Water retention
Joint pain
Carpal tunnel symptoms
Stop Signs - Discontinue if:
Severe joint pain or carpal tunnel syndrome
Excessive water retention affecting daily life
Numbness or tingling in extremities
Significant blood glucose dysregulation
Signs of acromegaly (jaw growth, hand/feet enlargement)
Persistent lethargy indicating adrenal effects
Contraindications
Diabetes history
Cancer history
Predisposed sleep apnea
Quality Checklist
Good Signs
High purity requirement (>98%); impurities cause more side effects
Proper DAC labeling; legitimate products clearly state 'with DAC'
Warning Signs
Higher cost than non-DAC (2-3x more due to complex manufacturing)
Foaming during mixing is normal for DAC peptides; wait for foam to settle
Bad Signs
Extremely cheap pricing (if priced similar to non-DAC, likely mislabeled)
Clear solution immediately (should be slightly cloudy initially)
Frequently Asked Questions
How much more expensive is CJC-1295 with DAC compared to without DAC?
CJC-1295 with DAC typically costs 2-3x more than the non-DAC version due to complex albumin-binding manufacturing. The higher cost reflects the DAC technology enabling weekly dosing versus daily injections required for the basic version, making weekly administration more convenient despite the price premium.
Is CJC-1295 with DAC safe to combine with testosterone therapy?
CJC-1295 with DAC can be used with testosterone but requires careful monitoring. Combining continuous GH elevation with exogenous testosterone increases risk of joint pain, water retention, and elevated IGF-1 beyond safe levels. Most protocols separate them or use lower doses of each when combined.
Why does some people report joint pain during CJC-1295 DAC use?
Joint pain and carpal tunnel symptoms occur due to sustained GH and IGF-1 elevation causing water retention in joints and connective tissues. Unlike pulsatile protocols where GH spikes then drops, the 6-8 day DAC half-life creates continuous elevation that may stress joints, particularly in high-dose users.
Can you switch between CJC-1295 with DAC and without DAC during a cycle?
Switching between variants mid-cycle is not recommended because they have different pharmacokinetics—DAC provides sustained elevation while non-DAC creates pulsatile release. Combining them risks excessive GH levels and unpredictable effects. Choose one variant at the start and maintain consistency throughout your cycle.
References
Subcutaneous CJC-1295 produced sustained, dose-dependent increases in GH and IGF-1 in healthy adults. Half-life of ~8 days. Cumulative effect after multiple doses with well-preserved GH pulsatility.
Basal (trough) GH levels increased 7.5-fold. Mean GH levels increased 46% and IGF-1 levels increased 45%. Pulsatile GH secretion preserved despite continuous GHRH receptor stimulation.
Identified CJC-1295 as a long-acting GHRH analog through albumin bioconjugation (DAC technology). Binds covalently to endogenous albumin, extending half-life from minutes to days.
Long-acting GHRH stimulation via CJC-1295 produces measurable changes in serum protein profiles reflecting sustained GH/IGF-1 axis activation.
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.